Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 534

1.

Bile acid metabolism and T cell responses in cholangiopathy: Not one-way traffic.

Shetty S, Boyer JL.

J Hepatol. 2019 Oct;71(4):657-659. doi: 10.1016/j.jhep.2019.07.012. Epub 2019 Aug 22. No abstract available.

PMID:
31447221
2.

Patient-Derived Organoids from Human Bile: An In Vitro Method to Study Cholangiopathies.

Soroka CJ, Assis DN, Boyer JL.

Methods Mol Biol. 2019;1981:363-372. doi: 10.1007/978-1-4939-9420-5_24.

PMID:
31016667
3.

Harold J. Fallon, M.D. (1931-2018).

Boyer JL.

Hepatology. 2019 May;69(5):2308-2309. doi: 10.1002/hep.30585. Epub 2019 Mar 27. No abstract available.

PMID:
30811607
4.

Bile-Derived Organoids From Patients With Primary Sclerosing Cholangitis Recapitulate Their Inflammatory Immune Profile.

Soroka CJ, Assis DN, Alrabadi LS, Roberts S, Cusack L, Jaffe AB, Boyer JL.

Hepatology. 2019 Sep;70(3):871-882. doi: 10.1002/hep.30470. Epub 2019 Mar 13.

PMID:
30561836
5.

H19 Is Expressed in Hybrid Hepatocyte Nuclear Factor 4α+ Periportal Hepatocytes but Not Cytokeratin 19+ Cholangiocytes in Cholestatic Livers.

Jiang Y, Huang Y, Cai S, Song Y, Boyer JL, Zhang K, Gao L, Zhao J, Huang W, Liang G, Liangpunsakul S, Wang L.

Hepatol Commun. 2018 Sep 24;2(11):1356-1368. doi: 10.1002/hep4.1252. eCollection 2018 Nov.

6.

Bile Infarcts: New Insights Into the Pathogenesis of Obstructive Cholestasis.

Cai SY, Boyer JL.

Hepatology. 2019 Feb;69(2):473-475. doi: 10.1002/hep.30291. Epub 2019 Jan 16. No abstract available.

PMID:
30251326
7.

Liver Complications Following Treatment of Hematologic Malignancy With Anti-CD22-Calicheamicin (Inotuzumab Ozogamicin).

McDonald GB, Freston JW, Boyer JL, DeLeve LD.

Hepatology. 2019 Feb;69(2):831-844. doi: 10.1002/hep.30222. Epub 2019 Jan 18.

PMID:
30120894
8.

Solute Carrier Organic Anion Transporter Family Member 3A1 Is a Bile Acid Efflux Transporter in Cholestasis.

Pan Q, Zhang X, Zhang L, Cheng Y, Zhao N, Li F, Zhou X, Chen S, Li J, Xu S, Huang D, Chen Y, Li L, Wang H, Chen W, Cai SY, Boyer JL, Chai J.

Gastroenterology. 2018 Nov;155(5):1578-1592.e16. doi: 10.1053/j.gastro.2018.07.031. Epub 2018 Jul 29.

PMID:
30063921
9.

Histologic features of autoimmune hepatitis: a critical appraisal.

Gurung A, Assis DN, McCarty TR, Mitchell KA, Boyer JL, Jain D.

Hum Pathol. 2018 Dec;82:51-60. doi: 10.1016/j.humpath.2018.07.014. Epub 2018 Jul 21.

PMID:
30041025
10.

Assessing cancer risk factors faced by an Ancestral Puebloan population in the North American Southwest.

Whitley CB, Boyer JL.

Int J Paleopathol. 2018 Jun;21:166-177. doi: 10.1016/j.ijpp.2017.06.004. Epub 2017 Aug 23.

PMID:
29778412
11.

OSTα-OSTβ Guards the Ileal Enterocyte From the Accumulation of Toxic Levels of Bile Acids.

Boyer JL.

Cell Mol Gastroenterol Hepatol. 2018 Feb 10;5(4):649-650. doi: 10.1016/j.jcmgh.2018.01.015. eCollection 2018. No abstract available.

12.

Cenicriviroc, a cytokine receptor antagonist, potentiates all-trans retinoic acid in reducing liver injury in cholestatic rodents.

Yu D, Cai SY, Mennone A, Vig P, Boyer JL.

Liver Int. 2018 Jun;38(6):1128-1138. doi: 10.1111/liv.13698. Epub 2018 Feb 13.

13.

Primary Sclerosing Cholangitis Is Not Rare Among Blacks in a Multicenter North American Consortium.

Goldberg DS, Levy C, Yimam K, Gordon SC, Forman L, Verna E, Yu L, Rahimi R, Schwarz K, Eksteen B, Pratt D, Boyer JL, Assis D, Bowlus C.

Clin Gastroenterol Hepatol. 2018 Apr;16(4):591-593. doi: 10.1016/j.cgh.2017.10.028. Epub 2017 Nov 2. No abstract available.

14.

Maintaining a Vibrant and Productive Laboratory as a Senior Investigator.

Boyer JL.

Cell Mol Gastroenterol Hepatol. 2017 Jun 7;4(2):299-300. doi: 10.1016/j.jcmgh.2017.04.008. eCollection 2017 Sep. No abstract available.

15.

Studies on the mechanisms of bile acid initiated hepatic inflammation in cholestatic liver injury.

Cai SY, Boyer JL.

Inflamm Cell Signal. 2017;4(2). pii: e1561. Epub 2017 Jun 19.

16.

Mechanisms of bile acid mediated inflammation in the liver.

Li M, Cai SY, Boyer JL.

Mol Aspects Med. 2017 Aug;56:45-53. doi: 10.1016/j.mam.2017.06.001. Epub 2017 Jul 1. Review.

17.

Bile acids initiate cholestatic liver injury by triggering a hepatocyte-specific inflammatory response.

Cai SY, Ouyang X, Chen Y, Soroka CJ, Wang J, Mennone A, Wang Y, Mehal WZ, Jain D, Boyer JL.

JCI Insight. 2017 Mar 9;2(5):e90780. doi: 10.1172/jci.insight.90780.

18.

The Role of Inflammation in the Mechanisms of Bile Acid-Induced Liver Damage.

Cai SY, Boyer JL.

Dig Dis. 2017;35(3):232-234. doi: 10.1159/000450916. Epub 2017 Mar 1.

19.

Na+-taurocholate cotransporting polypeptide (NTCP/SLC10A1) ortholog in the marine skate Leucoraja erinacea is not a physiological bile salt transporter.

Yu D, Zhang H, Lionarons DA, Boyer JL, Cai SY.

Am J Physiol Regul Integr Comp Physiol. 2017 Apr 1;312(4):R477-R484. doi: 10.1152/ajpregu.00302.2016. Epub 2017 Jan 11.

20.

Treatment of chronic cholestasis: What we know and what we will know?

Boyer JL.

Clin Liver Dis (Hoboken). 2016 Dec 30;8(6):140-144. doi: 10.1002/cld.591. eCollection 2016 Dec. Review. No abstract available.

21.

CFTR-associated ligand is a negative regulator of Mrp2 expression.

Li M, Soroka CJ, Harry K, Boyer JL.

Am J Physiol Cell Physiol. 2017 Jan 1;312(1):C40-C46. doi: 10.1152/ajpcell.00100.2016. Epub 2016 Nov 9.

22.

Sirtuin 1 activation alleviates cholestatic liver injury in a cholic acid-fed mouse model of cholestasis.

Kulkarni SR, Soroka CJ, Hagey LR, Boyer JL.

Hepatology. 2016 Dec;64(6):2151-2164. doi: 10.1002/hep.28826. Epub 2016 Oct 28.

23.

A Macrophage Migration Inhibitory Factor Polymorphism Is Associated with Autoimmune Hepatitis Severity in US and Japanese Patients.

Assis DN, Takahashi H, Leng L, Zeniya M, Boyer JL, Bucala R.

Dig Dis Sci. 2016 Dec;61(12):3506-3512. Epub 2016 Oct 1.

24.

Combination Therapy of All-Trans Retinoic Acid With Ursodeoxycholic Acid in Patients With Primary Sclerosing Cholangitis: A Human Pilot Study.

Assis DN, Abdelghany O, Cai SY, Gossard AA, Eaton JE, Keach JC, Deng Y, Setchell KD, Ciarleglio M, Lindor KD, Boyer JL.

J Clin Gastroenterol. 2017 Feb;51(2):e11-e16. doi: 10.1097/MCG.0000000000000591.

25.

A Novel Di-Leucine Motif at the N-Terminus of Human Organic Solute Transporter Beta Is Essential for Protein Association and Membrane Localization.

Xu S, Soroka CJ, Sun AQ, Backos DS, Mennone A, Suchy FJ, Boyer JL.

PLoS One. 2016 Jun 28;11(6):e0158269. doi: 10.1371/journal.pone.0158269. eCollection 2016.

26.

Canalicular membrane MRP2/ABCC2 internalization is determined by Ezrin Thr567 phosphorylation in human obstructive cholestasis.

Chai J, Cai SY, Liu X, Lian W, Chen S, Zhang L, Feng X, Cheng Y, He X, He Y, Chen L, Wang R, Wang H, Boyer JL, Chen W.

J Hepatol. 2015 Dec;63(6):1440-8. doi: 10.1016/j.jhep.2015.07.016. Epub 2015 Jul 23.

27.

Na(+) /H(+) exchanger regulatory factor 1 knockout mice have an attenuated hepatic inflammatory response and are protected from cholestatic liver injury.

Li M, Mennone A, Soroka CJ, Hagey LR, Ouyang X, Weinman EJ, Boyer JL.

Hepatology. 2015 Oct;62(4):1227-36. doi: 10.1002/hep.27956. Epub 2015 Aug 22.

28.

A Novel Small-Molecule Inhibitor Targeting CREB-CBP Complex Possesses Anti-Cancer Effects along with Cell Cycle Regulation, Autophagy Suppression and Endoplasmic Reticulum Stress.

Lee JW, Park HS, Park SA, Ryu SH, Meng W, Jürgensmeier JM, Kurie JM, Hong WK, Boyer JL, Herbst RS, Koo JS.

PLoS One. 2015 Apr 21;10(4):e0122628. doi: 10.1371/journal.pone.0122628. eCollection 2015.

29.

Controlled-release mitochondrial protonophore reverses diabetes and steatohepatitis in rats.

Perry RJ, Zhang D, Zhang XM, Boyer JL, Shulman GI.

Science. 2015 Mar 13;347(6227):1253-6. doi: 10.1126/science.aaa0672. Epub 2015 Feb 26.

30.

Fibrates and cholestasis.

Ghonem NS, Assis DN, Boyer JL.

Hepatology. 2015 Aug;62(2):635-43. doi: 10.1002/hep.27744. Epub 2015 Mar 23. Review.

31.

The origins of hepatobiliary and gastrointestinal physiology.

Boyer JL.

Hepatology. 2015 May;61(5):1452-4. doi: 10.1002/hep.27737. Epub 2015 Mar 18. No abstract available.

32.

The hepatobiliary paracellular pathway: a paradigm revisited.

Boyer JL.

Gastroenterology. 2014 Nov;147(5):965-8. doi: 10.1053/j.gastro.2014.09.018. Epub 2014 Sep 26. No abstract available.

PMID:
25263297
33.

Bis(imino)pyridine cobalt-catalyzed dehydrogenative silylation of alkenes: scope, mechanism, and origins of selective allylsilane formation.

Atienza CC, Diao T, Weller KJ, Nye SA, Lewis KM, Delis JG, Boyer JL, Roy AK, Chirik PJ.

J Am Chem Soc. 2014 Aug 27;136(34):12108-18. doi: 10.1021/ja5060884. Epub 2014 Aug 12.

PMID:
25068530
34.

A RAS renaissance: emerging targeted therapies for KRAS-mutated non-small cell lung cancer.

Vasan N, Boyer JL, Herbst RS.

Clin Cancer Res. 2014 Aug 1;20(15):3921-30. doi: 10.1158/1078-0432.CCR-13-1762. Epub 2014 Jun 3. Review.

35.

Glucocerebrosidase 2 gene deletion rescues type 1 Gaucher disease.

Mistry PK, Liu J, Sun L, Chuang WL, Yuen T, Yang R, Lu P, Zhang K, Li J, Keutzer J, Stachnik A, Mennone A, Boyer JL, Jain D, Brady RO, New MI, Zaidi M.

Proc Natl Acad Sci U S A. 2014 Apr 1;111(13):4934-9. doi: 10.1073/pnas.1400768111. Epub 2014 Mar 17.

36.

All-trans-retinoic acid improves cholestasis in α-naphthylisothiocyanate-treated rats and Mdr2-/- mice.

Cai SY, Mennone A, Soroka CJ, Boyer JL.

J Pharmacol Exp Ther. 2014 Apr;349(1):94-8. doi: 10.1124/jpet.113.209353. Epub 2014 Feb 3.

37.

Altered expression and function of canalicular transporters during early development of cholestatic liver injury in Abcb4-deficient mice.

Cai SY, Mennone A, Soroka CJ, Boyer JL.

Am J Physiol Gastrointest Liver Physiol. 2014 Apr 15;306(8):G670-6. doi: 10.1152/ajpgi.00334.2013. Epub 2014 Jan 30.

38.

"Quitting smoking will benefit your health": the evolution of clinician messaging to encourage tobacco cessation.

Toll BA, Rojewski AM, Duncan LR, Latimer-Cheung AE, Fucito LM, Boyer JL, O'Malley SS, Salovey P, Herbst RS.

Clin Cancer Res. 2014 Jan 15;20(2):301-9. doi: 10.1158/1078-0432.CCR-13-2261. Epub 2014 Jan 16. Review.

39.

Ostα-/- mice exhibit altered expression of intestinal lipid absorption genes, resistance to age-related weight gain, and modestly improved insulin sensitivity.

Wheeler SG, Hammond CL, Jornayvaz FR, Samuel VT, Shulman GI, Soroka CJ, Boyer JL, Hinkle PM, Ballatori N.

Am J Physiol Gastrointest Liver Physiol. 2014 Mar 1;306(5):G425-38. doi: 10.1152/ajpgi.00368.2013. Epub 2013 Dec 31.

40.
41.

Deleterious effect of oltipraz on extrahepatic cholestasis in bile duct-ligated mice.

Weerachayaphorn J, Luo Y, Mennone A, Soroka CJ, Harry K, Boyer JL.

J Hepatol. 2014 Jan;60(1):160-6. doi: 10.1016/j.jhep.2013.08.015. Epub 2013 Aug 23.

42.

The role of macrophage migration inhibitory factor in autoimmune liver disease.

Assis DN, Leng L, Du X, Zhang CK, Grieb G, Merk M, Garcia AB, McCrann C, Chapiro J, Meinhardt A, Mizue Y, Nikolic-Paterson DJ, Bernhagen J, Kaplan MM, Zhao H, Boyer JL, Bucala R.

Hepatology. 2014 Feb;59(2):580-91. doi: 10.1002/hep.26664. Epub 2013 Dec 20.

43.

Bile formation and secretion.

Boyer JL.

Compr Physiol. 2013 Jul;3(3):1035-78. doi: 10.1002/cphy.c120027. Review.

44.

Biosynthesis and trafficking of the bile salt export pump, BSEP: therapeutic implications of BSEP mutations.

Soroka CJ, Boyer JL.

Mol Aspects Med. 2014 Jun;37:3-14. doi: 10.1016/j.mam.2013.05.001. Epub 2013 May 15. Review.

45.

A step towards treating KRAS-mutant NSCLC.

Goldberg SB, Schlessinger J, Boyer JL, Herbst RS.

Lancet Oncol. 2013 Jan;14(1):3-5. doi: 10.1016/S1470-2045(12)70528-4. Epub 2012 Nov 28. No abstract available.

PMID:
23200176
46.

Adult sea lamprey tolerates biliary atresia by altering bile salt composition and renal excretion.

Cai SY, Lionarons DA, Hagey L, Soroka CJ, Mennone A, Boyer JL.

Hepatology. 2013 Jun;57(6):2418-26. doi: 10.1002/hep.26161.

47.

Fibrates as adjuvant therapy for chronic cholestatic liver disease: its time has come.

Ghonem NS, Boyer JL.

Hepatology. 2013 May;57(5):1691-3. doi: 10.1002/hep.26155. Epub 2013 Apr 5. No abstract available.

48.

Evolution of substrate specificity for the bile salt transporter ASBT (SLC10A2).

Lionarons DA, Boyer JL, Cai SY.

J Lipid Res. 2012 Aug;53(8):1535-42. doi: 10.1194/jlr.M025726. Epub 2012 Jun 5.

49.

A cholecystohepatic shunt pathway: does the gallbladder protect the liver?

Boyer JL, Soroka CJ.

Gastroenterology. 2012 Jun;142(7):1416-9. doi: 10.1053/j.gastro.2012.04.036. Epub 2012 Apr 26. No abstract available.

PMID:
22542828
50.

Targeting vascular endothelial growth factor in patients with squamous cell lung cancer.

Koo PJ, Morgensztern D, Boyer JL, Herbst RS.

J Clin Oncol. 2012 Apr 1;30(10):1137-9. doi: 10.1200/JCO.2011.40.4053. Epub 2012 Feb 21. No abstract available.

PMID:
22355057

Supplemental Content

Loading ...
Support Center